NCT04847804

Large-scale COVID-19 Population Screening

Status unknown Last updated 1 March 2023

What this trial tests

trial in Covid19 in 200 participants. Status unknown.

Timeline

1 July 2021

Primary endpoint
31 May 2024

31 May 2024

Quick facts

Lead sponsor	Hong Kong University of Science and Technology
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	1 July 2021
Primary completion	31 May 2024
Estimated completion	31 May 2024
Sites	3 locations across Hong Kong

Conditions studied

• Covid19 — all drugs for Covid19 →

Sponsor

Hong Kong University of Science and Technology

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Infectious diseases pose a threat to the life of individuals worldwide. The pandemic has highlighted the need to develop an innovative and cost- effective large population-based screening methodology. The investigators propose a two-fold improvement barcode-labeled testing strategy specifically for pooled samples. This platform combines isothermal amplification and real-time electrochemical detection; electroactive modified loop probes will be used in the amplification step for barcode readout. This method enables four samples pooled detection at the same time. This platform will be integrated into a disposable microfluidic chip that allows minimal human intervention during the process to realize a massively parallel screening platform for infectious disease pathogens.

Objectives

1. To develop a sensing method for concurrent electrochemical-tag coded isothermal amplification and real-time electrochemical detection;
2. To design a molecular strategy to barcode four individual samples so that they can be pooled together and to simultaneously amplify and identify a positive individual, if any, from the pooled sample.
3. To fabricate a microfluidic device integrating the sample processor and barcoding module with the nucleic acid amplification and detection step for large-scale population screening of up to 100 individuals.
4. To validate the performance of the prototype using clinical specimens and benchmark it against the detection data from commercially available testing equipment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Organ-on-chip for advancing CAR therapy.
   Ngashangva L, Martin S. · · 2025 · cited 2× · PMID 40018376 · DOI 10.1002/cti2.70024